Adicet Bio, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Adicet Bio, Inc. (ACET) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$1.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-05
- Adicet Bio, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was -$750.00K, a 146.04% decline year-over-year.
- Adicet Bio, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$1.15M.
- Adicet Bio, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $1.93M.
- Adicet Bio, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $538.00K.
- Adicet Bio, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $1.90M.
- Adicet Bio, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was -$2.02M, a 369.60% decline from fiscal 2023.
- Adicet Bio, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $750.00K, a 87.14% decline from fiscal 2022.
- Adicet Bio, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $5.83M, a 589.24% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$750.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$1.90M 10-Q · filed 2026-08-05 | $39.00K derived: sum of 3 quarters · filed 2026-08-05 | $577.00K derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2026-03-31 | -$1.15M 10-Q · filed 2026-05-13 | $789.00K derived: sum of 2 quarters · filed 2026-05-13 | $1.33M derived: sum of 3 quarters · filed 2026-05-13 | $2.96M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-12-31 | $1.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $2.47M derived: sum of 2 quarters · filed 2026-03-12 | $4.10M derived: sum of 3 quarters · filed 2026-08-05 | $1.90M 10-K · filed 2026-03-12 | ||
| 2025-09-30 | $538.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $2.17M derived: sum of 2 quarters · filed 2026-08-05 | -$30.00K 10-Q · filed 2025-11-05 | -$919.00K derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-06-30 | $1.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$568.00K 10-Q · filed 2026-08-05 | -$1.46M derived: sum of 3 quarters · filed 2026-08-05 | -$1.79M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-03-31 | -$2.20M 10-Q · filed 2026-05-13 | -$3.09M derived: sum of 2 quarters · filed 2026-05-13 | -$3.42M derived: sum of 3 quarters · filed 2026-05-13 | -$2.44M derived: sum of 4 quarters · filed 2026-05-13 | ||
| 2024-12-31 | -$889.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$1.22M derived: sum of 2 quarters · filed 2026-03-12 | -$247.00K derived: sum of 3 quarters · filed 2026-03-12 | -$2.02M 10-K · filed 2026-03-12 | ||
| 2024-09-30 | -$334.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $642.00K derived: sum of 2 quarters · filed 2025-11-05 | -$1.13M 10-Q · filed 2025-11-05 | -$419.00K derived: sum of 4 quarters · filed 2025-11-05 | ||
| 2024-06-30 | $976.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$799.00K 10-Q · filed 2025-08-07 | -$85.00K derived: sum of 3 quarters · filed 2025-08-07 | -$68.00K derived: sum of 4 quarters · filed 2025-08-07 | ||
| 2024-03-31 | -$1.77M 10-Q · filed 2025-05-06 | -$1.06M derived: sum of 2 quarters · filed 2025-05-06 | -$1.04M derived: sum of 3 quarters · filed 2025-05-06 | -$776.00K derived: sum of 4 quarters · filed 2025-05-06 | ||
| 2023-12-31 | $714.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $731.00K derived: sum of 2 quarters · filed 2025-03-06 | $999.00K derived: sum of 3 quarters · filed 2025-03-06 | $750.00K 10-K · filed 2025-03-06 | ||
| 2023-09-30 | $17.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $285.00K derived: sum of 2 quarters · filed 2024-11-06 | $36.00K 10-Q · filed 2024-11-06 | $5.02M derived: sum of 4 quarters · filed 2024-11-06 | ||
| 2023-06-30 | $268.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $19.00K 10-Q · filed 2024-08-13 | $5.00M derived: sum of 3 quarters · filed 2024-08-13 | $4.29M derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2023-03-31 | -$249.00K 10-Q · filed 2024-05-14 | $4.74M derived: sum of 2 quarters · filed 2024-05-14 | $4.02M derived: sum of 3 quarters · filed 2024-05-14 | $7.08M derived: sum of 4 quarters · filed 2024-05-14 | ||
| 2022-12-31 | $4.99M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $4.27M derived: sum of 2 quarters · filed 2024-03-19 | $7.33M derived: sum of 3 quarters · filed 2024-03-19 | $5.83M 10-K · filed 2024-03-19 | $5.65M 10-K · filed 2023-03-15 | |
| 2022-09-30 | -$712.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $2.34M derived: sum of 2 quarters · filed 2023-11-08 | $846.00K 10-Q · filed 2023-11-08 | $2.82M derived: sum of 4 quarters · filed 2023-11-08 | ||
| 2022-06-30 | $3.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $1.56M 10-Q · filed 2023-08-09 | $3.53M derived: sum of 3 quarters · filed 2023-08-09 | $3.82M derived: sum of 4 quarters · filed 2023-08-09 | ||
| 2022-03-31 | -$1.50M 10-Q · filed 2023-05-09 | $477.00K derived: sum of 2 quarters · filed 2023-05-09 | $761.00K derived: sum of 3 quarters · filed 2023-05-09 | $902.00K derived: sum of 4 quarters · filed 2023-05-09 | ||
| 2021-12-31 | $1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $2.26M derived: sum of 2 quarters · filed 2023-03-15 | $2.40M derived: sum of 3 quarters · filed 2023-03-15 | $846.00K 10-K · filed 2023-03-15 | $855.00K 10-K · filed 2022-03-15 | |
| 2021-09-30 | $284.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $425.00K derived: sum of 2 quarters · filed 2022-11-08 | -$1.13M 10-Q · filed 2022-11-08 | -$1.24M 10-Q · filed 2021-11-10 | -$2.08M derived: sum of 4 quarters · filed 2022-11-08 | |
| 2021-06-30 | $141.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$1.41M 10-Q · filed 2022-08-10 | -$2.36M derived: sum of 3 quarters · filed 2022-08-10 | -$4.10M derived: sum of 4 quarters · filed 2022-08-10 | ||
| 2021-03-31 | -$1.55M 10-Q · filed 2022-05-12 | -$2.50M derived: sum of 2 quarters · filed 2022-05-12 | -$4.24M derived: sum of 3 quarters · filed 2022-05-12 | -$1.34M derived: sum of 4 quarters · filed 2022-05-12 | ||
| 2020-12-31 | -$951.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$2.69M derived: sum of 2 quarters · filed 2022-03-15 | $216.00K derived: sum of 3 quarters · filed 2022-03-15 | $787.00K 10-K · filed 2022-03-15 | ||
| 2020-09-30 | -$1.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $1.17M derived: sum of 2 quarters · filed 2021-11-10 | $1.74M 10-Q · filed 2021-11-10 | $2.00M derived: sum of 4 quarters · filed 2021-11-10 | ||
| 2020-06-30 | $2.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $3.48M 10-Q · filed 2021-08-12 | $3.74M derived: sum of 3 quarters · filed 2021-08-12 | |||
| 2020-03-31 | $571.00K 10-Q · filed 2021-05-17 | $838.00K derived: sum of 2 quarters · filed 2021-05-17 | ||||
| 2019-12-31 | $267.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | -$360.00K 10-K · filed 2021-03-12 | ||||
| 2019-09-30 | -$627.00K 10-Q · filed 2020-11-05 | |||||
| 2018-12-31 | -$1.32M 10-K · filed 2021-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |